Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute (FCSRI), discusses what guests can expect at the in-person Tampa meeting of The American Journal of Managed Care®'s Institute for Value-Based Medicine® (IVBM), co-hosted by FCSRI.
In-person attendees of the upcoming Institute for Value-Based Medicine® (IVBM) meeting in Tampa, Florida, can expect rich dialogue regarding the state of oncology care today, including physician burnout, advancements in therapeutics, and more, said Nathan H. Walcker, MBA, chief executive officer, Florida Cancer Specialists & Research Institute.
Transcript
What should guests of the upcoming Tampa IVBM meeting look forward to?
First and foremost, I couldn't be more excited to be hosting the event and having a number of our clinical leaders and administrative leaders be participating. Ultimately, what folks can expect when it comes to that is a really rich dialogue around the state of oncology care today and recognizing that we've come a long way over the past 5 years; more specifically, through the COVID-19 pandemic.
Really unpacking a lot of the issues that we all know are out there, but doing so in 1 session, in 1 day. Hearing from folks on physician burnout, looking at great opportunities in clinical trials and advancements in therapeutics. And again, getting together with like-minded stakeholders that are making sure that at the end of the day, it would take a village to provide oncology care. And if we have an opportunity together to learn from one another, what better place to do it than in Tampa. Unfortunately, it's not football season, but there's enough sports to go around and the weather's not too bad either.
Inside the Center's MDD Value Model and Its Use of Dynamic Pricing
May 13th 2025Larragem Raines, MS, of the Center for Innovation & Value Research, discusses the organization's major depressive disorder (MDD) open-source value model, dynamic pricing, and the future role of artificial intelligence in care.
Listen
Quantitative Magnetic Resonance Outcomes Suggest Gene Therapy Slows DMD Progression
May 14th 2025Delandistrogene moxeparvovec (Elevidys; Sarepta Therapeutics) appeared to protect muscle from progressive damage in patients with Duchenne muscular dystrophy (DMD) based on muscle quantitative magnetic resonance measures.
Read More
Digital Health Implementation Among Older Adults: Health Technology Navigators’ Perspectives
May 14th 2025Health technology navigators share perspectives on barriers to and facilitators of digital health access for older, linguistically diverse patients in a Los Angeles safety-net system.
Read More